Latest Co-Diagnostics News & Updates

See the latest news and media coverage for Co-Dx. We track all announcements, press releases, and industry mentions in real time, all in one place.

Co-Diagnostics (Co-Dx)

Real-time PCR diagnostic test developer

co-dx.com

Headquarters: Salt Lake City, United States
Founded year: 2013
Company type: Public company
Number of employees: 80–200
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Co-Diagnostics (Co-Dx)

In short: Co-Dx advanced Ebola and TB diagnostics, filed an FDA 510(k) for its respiratory test, and expanded globally despite a Q2 net loss.

Company announcements

August 13 Co-Dx

Co-Dx reports Q2 2026 net loss of $6.3 million

Revenue was $0.17M and the company filed a 510(k) for its respiratory test and expanded in Saudi Arabia.

August 6 Co-Dx

Co-Dx submits FDA 510(k) for upper respiratory point-of-care test

The submission includes a concurrent CLIA Waiver by Application for use on the Co-Dx PCR Pro instrument in decentralized settings, following clinical studies with over 1,400 patients.

July 22 Co-Dx

Co-Dx joint venture CoSara initiates TB test clinical studies in India

PCR Pro instruments and MTB test kits deployed to select labs for evaluation, delivering rapid PCR results in 30 minutes.

July 16 Co-Dx

Co-Dx appoints Wes Lindsey as Chief Scientific Officer

He brings over 20 years of molecular diagnostics experience and will lead R&D for FDA submissions.

Media coverage

August 18 Law360

COVID Test-Maker Inks $6.5M Investor Deal Over Sales Slump - Law360

Co-Diagnostics Inc. has agreed to pay $6.5 million to settle an investor lawsuit accusing it of overstating the demand for its COVID-19 testing kits two...

August 13 Yahoo Finance

Co-Dx (CODX) Q2 2026 Earnings Call Transcript

Second Quarter 26 Earnings Webcast. All lines have been placed on mute to prevent any background noise. After the speaker's ...

August 6 Yahoo Finance

Co-Diagnostics files FDA 510(k) for flu and RSV PCR test

The molecular diagnostics company's concurrent CLIA Waiver by Application, if granted, would allow testing in decentralised point-of-care settings.

July 28 The Globe and Mail

Co-Diagnostics Amends Equity Distribution, Extends Issuance Limits

Detailed price information for Co-Diagnostics Inc (CODX-Q) from The Globe and Mail including charting and trades.

Never miss news about Co-Dx

Track Co-Dx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Co-Dx competitors & trending companies

Browse news for competitors to Co-Dx and other trending companies.